Second malignant tumors in pediatric cancer survivors


Cite item

Full Text

Abstract

The development of a second malignancy is one of the most serious late effect for children who have been cured from the first malignancy. Chemoradiotherapy is a carcinogenic factor of the developing of the second malignancy. Organs and tissues of the child's body, taking into account the degree of maturity, microenvironment, age and life factors, are differently susceptible to the carcinogenic effects of chemo- and radiation therapy. Given the increase in the number of patients cured from the first malignancy, improving therapy is aimed at reducing the risk of developing a second malignancy as the child's body grows and develops. Determining the risk factors for secondary malignancy and developing measures aimed at reducing the frequency of secondary tumors in pediatric cancer survivors is an important task of modern oncopediatry. This paper presents the most common childhood tumors, after treatment of which the development of the second malignancy occurs. Risk factors and timing of secondary tumors are highlighted. Special attention is paid to recommendations for monitoring people who have been cured of malignancy in childhood.

Full Text

Restricted Access

About the authors

Tatiana Yu. Pavlova

Blokhin National Medical Research Center of Oncology

Moscow, Russia

Timur T. Valiev

Blokhin National Medical Research Center of Oncology

Email: timurvaliev@mail.ru
Moscow, Russia

References

  1. Ries L, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2004. Bethesda: National Cancer Institute; 2007.
  2. Meadows AT, Friedman DL, Neglia JP et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27 (14): 2356-62.
  3. Moller TR, Garwicz S, Barlow L et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 2001; 19 (13): 3173-81.
  4. Skvortsova Iu.V., Balashov V.N., Shelikhova L.N. et al. Vtorichnye solidnye opukholi u detei posle allogennoi transplantatsii gemopoeticheskikh stvolovykh kletok (kli-nicheskie sluchai i obzor literatury). Onkogematologiia. 2017; 12 (2): 39-53 (in Russian).
  5. Travis LB, Rabkin CS, Brown LM et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006; 98 (1): 15-25.
  6. Neglia JP, Friedman DL, Yasui Y et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001; 93 (8): 618-29.
  7. Curtis R, Freedman D, Ron E et al. New Malignancies Among Cancer Survivors: SEER Cancer Registriesю National Cancer Institute; Bethesda, MD: 2006; p. 19732000.
  8. Hijiya N, Hudson MM, Lensing S et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007; 297 (11): 1207-15.
  9. Neglia JP, Meadows AT, Robison LL et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325 (19): 1330-6.
  10. Loning L, Zimmermann M, Reiter A et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000; 95 (9): 2770-5.
  11. Bhatia S, Sather HN, Pabustan OB et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002; 99 (12): 4257-64.
  12. Neglia JP, Robison LL, Stovall M et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006; 98 (21): 1528-37.
  13. Walter AW, Hancock ML, Pui CH et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol 1998; 16 (12): 3761-7.
  14. Nobuko Hijiya, Ness KK, Ribeiro RC. Acute Leukemia as a Secondary Malignancy in Children and Adolescents: Current Findings and Issues. Cancer 2009; 115 (1): 2335. doi: 10.1002/cncr.23988
  15. Swerdlow SH, Campo E, Harris NL et al. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon, 2017.
  16. Smith SM, Le Beau MM, Huo D et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102 (1): 43-52.
  17. Relling MV, Rubnitz JE, Rivera GK et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354 (9172): 34-9.
  18. Pui CH, Relling MV, Rivera GK et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 1995; 9 (12): 1990-6.
  19. Van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994; 12 (5): 1063-73.
  20. Le Deley MC, Vassal G, TaXbi A et al. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer 2005; 45 (1): 25-31.
  21. Haddy N, Le Deley MC, Samand A et al. Role of radiotherapy and chemotherapy in the risk of secondary leukaemia after a solid tumour in childhood. Eur J Cancer 2006; 42 (16): 2757-64.
  22. Cavenee WK, Murphree AL, Shull MM et al. Prediction of familial predisposition to retinoblastoma. N Engl J Med 1986; 314 (19): 1201-7.
  23. Kleinerman RA, Tucker MA, Tarone RE et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005; 23 (10): 2272-9.
  24. Fletcher O, Easton D, Anderson K et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004; 96 (5): 357-63.
  25. Marees T, Moll AC, Imhof SM et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008; 100 (24): 1771-9.
  26. Hawkins MM, Wilson LM, Burton HS et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996; 88 (5): 270-8.
  27. Wong FL, Boice JD Jr, Abramson DH et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997; 278 (15): 1262-7.
  28. Kivela T Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 1999; 17 (6): 1829-837.
  29. Constine LS, Tarbell N, Hudson MM et al. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys 2008; 72 (1): 24-33.
  30. Bhatia S, Yasui Y, Robison LL et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003; 21 (23): 4386-94.
  31. Sankila R, Garwicz S, Olsen JH et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 1996; 14 (5): 1442-6.
  32. Ng AK, Bernardo MV, Weller E et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100 (6): 1989-96.
  33. Swerdlow AJ, Barber JA, Hudson GV et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000; 18 (3): 498-509.
  34. Green DM, Hyland A, Barcos MP et al. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol 2000; 18 (7): 1492-9.
  35. Kenney LB, Yasui Y, Inskip PD et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med 2004; 141 (8): 590-7.
  36. Curtis RE, Metayer C, Rizzo JD et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105 (10): 3802-11.
  37. Mauch P, Ng A, Aleman B et al. Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol Suppl 2005; 66: 68-76.
  38. Travis LB, Hill DA, Dores GM et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease [published correction appears in JAMA 2003; 290 (10): 1318]. JAMA 2003; 290 (4): 465-75.
  39. Van Leeuwen FE, Klokman WJ, Stovall M et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003; 95 (13): 971-80.
  40. Guibout C, Adjadj E, Rubino C et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol 2005; 23 (1): 197-204.
  41. Travis LB, Hill D, Dores GM et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97 (19): 1428-37.
  42. Sklar C, Whitton J, Mertens A et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000; 85 (9): 3227-32.
  43. Van Leeuwen FE, Klokman WJ, Veer MB et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18 (3): 487-97.
  44. Sigurdson AJ, Ronckers CM, Mertens AC et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 2005; 365 (9476): 2014-23.
  45. Acharya S, Sarafoglou K, LaQuaglia M et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer 2003; 97 (10): 2397-403.
  46. Black P, Straaten A, Gutjahr P. Secondary thyroid carcinoma after treatment for childhood cancer. Med Pediatr Oncol 1998; 31 (2): 91-5.
  47. Tucker MA, Jones PH, Boice JD Jr et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res 1991; 51 (11): 2885-8.
  48. Schneider AB, Ron E, Lubin J et al. Dose-response relationships for radiation-induced thyroid cancer and thyroid nodules: evidence for the prolonged effects of radiation on the thyroid. J Clin Endocrinol Metab 1993; 77 (2): 362-9.
  49. Bassal M, Mertens AC, Taylor L et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2006; 24 (3): 476-83.
  50. Walker DA, Perilongo G, Punt JAG et al. Brain and spinal tumors of childhood. Arnold, 2004; p. 314-330.
  51. Matsko D.E., Korshunov A.G. Atlas of tumors of the central nervous system. Saint Petersburg, 1998; p. 76-80 (in Russian).
  52. Galloway TJ, Indelicato DJ, Amdur RJ et al. Favorable outcomes of pediatric patients treated with radiotherapy to the central nervous system who develop radiation-induced meningiomas. Int J Radiat Oncol Biol Phys 2011; 79 (1): 117-20.
  53. Jenkinson HC, Hawkins MM, Stiller CA et al. Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer 2004; 91 (11): 1905-10.
  54. Mertens AC, Yasui Y, Neglia JP et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001; 19 (13): 3163-72.
  55. Tucker MA, D'Angio GJ, Boice JD Jr et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317 (10): 588-93.
  56. Kleinerman RA, Tucker MA, Abramson DH et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 2007; 99 (1): 24 31.
  57. Broniscer A, Ke W, Fuller CE et al. Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. Cancer 2004; 100 (10): 2246-52.
  58. Jenkin D, Greenberg M, Hoffman H et al. Brain tumors in children: long-term survival after radiation treatment. Int J Radiat Oncol Biol Phys 1995; 31 (3): 445-51.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies